Layer P, Jansen J B, Cherian L, Lamers C B, Goebell H
Department of Medicine, University of Essen, Federal Republic of Germany.
Gastroenterology. 1990 May;98(5 Pt 1):1311-9.
To determine the effects of luminal protease inhibition on duodenal delivery and the intraluminal fate of pancreatic enzymes, six healthy subjects were intubated with an oro-ileal multilumen tube assembly. By using nonabsorbable markers, cumulative trypsin, chymotrypsin, lipase, and amylase activities were measured as delivered to duodenum, midjejunum, and distal ileum, with or without simultaneous duodenal perfusion of the protease inhibitor camostat at graded doses. Compared with saline, camostat (a) inhibited trypsin activity in the entire small intestinal lumen by up to 99%, and significantly reduced chymotrypsin activity by up to 89%; (b) significantly increased duodenal deliveries of lipase activity, amylase activity and volume; (c) did not influence plasma cholecystokinin concentrations; and (d) significantly increased jejunal and ileal deliveries of lipase but not amylase activity. Small intestinal transit and motility were not affected by camostat. In additional in vitro studies, camostat significantly reduced the spontaneous decline in lipase activity in fresh human duodenal juice incubated at 37 degrees C. These findings demonstrate that duodenal deliveries of lipase and amylase activities increase when intraluminal protease activity is decreased; they suggest that this increase is not caused by slower proteolytic destruction of enzyme protein but by stimulation of pancreatic secretion. Thus, luminal protease-mediated feedback regulation of pancreatic secretion may be operative in humans. Because plasma cholecystokinin concentrations were not affected, these effects may in part be independent of cholecystokinin. The data further suggest that proteolytic digestion plays a major role in the rapid loss of luminal lipase activity on small intestinal transit.
为了确定肠腔蛋白酶抑制对十二指肠输送及胰酶肠腔内转归的影响,对6名健康受试者经口插入回肠多腔管组件。通过使用不可吸收标记物,在有或无同时以梯度剂量十二指肠灌注蛋白酶抑制剂抑肽酶的情况下,测量输送至十二指肠、空肠中段和回肠末端的累积胰蛋白酶、糜蛋白酶、脂肪酶和淀粉酶活性。与生理盐水相比,抑肽酶(a)在整个小肠腔内抑制胰蛋白酶活性高达99%,并显著降低糜蛋白酶活性高达89%;(b)显著增加十二指肠脂肪酶活性、淀粉酶活性和容量的输送;(c)不影响血浆胆囊收缩素浓度;(d)显著增加空肠和回肠脂肪酶的输送,但不影响淀粉酶活性。小肠转运和动力不受抑肽酶影响。在另外的体外研究中,抑肽酶显著降低了在37℃孵育的新鲜人十二指肠液中脂肪酶活性的自发下降。这些发现表明,当肠腔内蛋白酶活性降低时,十二指肠脂肪酶和淀粉酶活性的输送增加;提示这种增加不是由于酶蛋白的蛋白水解破坏减慢所致,而是由于胰腺分泌的刺激。因此,肠腔蛋白酶介导的胰腺分泌反馈调节在人类中可能起作用。由于血浆胆囊收缩素浓度未受影响,这些作用可能部分独立于胆囊收缩素。数据进一步提示,蛋白水解消化在小肠转运过程中肠腔脂肪酶活性的快速丧失中起主要作用。